Salix Coronary Plaque vs DeepRhythmAI
AI Verdict
Choose Salix Coronary Plaque if…
Choose Salix Coronary Plaque if your primary need is a rapid, AI-driven assessment of coronary artery plaque and stenosis directly from CCTA scans. This tool is ideal for cardiologists and radiologists seeking to quantify plaque burden, identify high-risk plaque features, and streamline the diagnosis of coronary artery disease at the point of care.
View Salix Coronary Plaque →Choose DeepRhythmAI if…
Choose DeepRhythmAI if your focus is on enhancing the accuracy and efficiency of cardiac arrhythmia detection and classification from ECG data. This AI algorithm is best suited for healthcare providers who process a high volume of ECGs and require a device-agnostic solution to reduce missed diagnoses and significantly streamline their reporting workflows.
View DeepRhythmAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Salix Coronary Plaque | DeepRhythmAI |
|---|---|---|
| Pricing | Subscription model | Contact vendor for pricing information |
| Deployment | Cloud-based (Amazon Web Services), web-based software application | Cloud-based, hardware-agnostic, SaaS, on-prem, hybrid |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
DeepRhythmAIDeepRhythmAI emphasizes its 'device-agnostic' nature and claims significant workflow efficiency increases (up to 65%), suggesting broader and more flexible integration into diverse clinical environments. While Salix Coronary Plaque is web-based and focuses on point-of-care, DeepRhythmAI's adaptability and quantifiable efficiency gains give it an edge in overall usability.
Clinical Value
DeepRhythmAIDeepRhythmAI provides specific, quantifiable metrics for reducing missed diagnoses (14x to 114x fewer) and is trained on an exceptionally large dataset of over 250 billion annotated heartbeats. These direct, quantified improvements in diagnostic accuracy make its clinical value highly compelling.
Pricing & Value
Salix Coronary PlaqueSalix Coronary Plaque offers a transparent pricing model based on a per-scan assessment, directly linking to a US CPT reimbursement rate of US$950. This provides a clear understanding of its economic value and potential for revenue generation for healthcare providers, unlike DeepRhythmAI's undisclosed 'enterprise' pricing.
Enterprise Readiness
DeepRhythmAIDeepRhythmAI explicitly highlights an 'API available' and targets 'Solo to large health systems' with 'numerous healthcare providers globally' as customers, alongside a longer company history since 2005. These factors collectively demonstrate a stronger focus on enterprise-level integration, scalability, and proven adoption in diverse healthcare environments.
Innovation
DeepRhythmAIDeepRhythmAI demonstrates a higher degree of technical innovation by explicitly mentioning the use of advanced AI models (CNN and Transformer) and being trained on an exceptionally massive dataset of over 250 billion annotated heartbeats. This indicates a more sophisticated and robust underlying AI methodology.
Support & Docs
Salix Coronary PlaqueSalix Coronary Plaque explicitly mentions the availability of an 'Artrya Salix User Guide' for its web-based software, suggesting direct end-user documentation and support. While DeepRhythmAI offers 'Product information' for specialists and integrates via API, the explicit mention of a user guide for Salix Coronary Plaque implies a more accessible and direct support structure for clinical end-users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Salix Coronary Plaque | DeepRhythmAI |
|---|---|---|
| Product Name | Salix Coronary Plaque | DeepRhythmAI |
| Company | Artrya Limited | Medicalgorithmics S.A. |
| Description | FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. | FDA-cleared, cloud-based AI algorithm that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians. |
| Primary Function | Detection and quantification of coronary plaque (atherosclerosis) and stenosis from CCTA scans. | Cardiac arrhythmia detection and classification from ECG data. |
| Key Features | AI-enabled CCTA analysis, Near real-time, point-of-care assessment, Detection and quantification of coronary plaque (atherosclerosis), Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), Stenosis assessment, Quantification of calcifications (calcium scoring), Integrated workflow management, Automated report generation (editable). | AI-powered arrhythmia detection and classification, Utilizes CNN and Transformer models, Trained on 250 billion+ annotated heartbeats, Device-agnostic and integrates with various ECG devices, Cloud-based software, Faster ECG reporting and analysis, Reduces missed diagnoses (14x to 114x fewer), Streamlines clinical workflows (up to 65% efficiency increase). |
| Specialties | Cardiology, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and DeepRhythmAI.